Advertisement
Advertisement
U.S. markets open in 1 hour 1 minute
Advertisement
Advertisement
Advertisement
Advertisement

Larimar Therapeutics, Inc. (LRMR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.3700+0.0400 (+1.20%)
At close: 04:00PM EDT
3.3000 -0.07 (-2.08%)
Pre-Market: 08:05AM EDT
Advertisement

Larimar Therapeutics, Inc.

Three Bala Plaza East
Suite 506
Bala Cynwyd, PA 19004
United States
844 511 9056
https://www.larimartx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees31

Key Executives

NameTitlePayExercisedYear Born
Dr. Carole S. Ben-Maimon M.D.CEO, Pres & Director663.43kN/A1959
Mr. Michael Celano CPASec. & CFO447.61kN/A1959
Mr. John BermanVP of Fin. & OperationsN/AN/AN/A
Ms. Jennifer Spokes JohanssonVP of Regulatory Affairs & CounselN/AN/AN/A
Dr. Nancy M. RuizChief Medical OfficerN/AN/AN/A
Mr. Francis Michael ConwayVP & ControllerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Corporate Governance

Larimar Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement